Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Quanta Services Inc (PWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Quanta Services Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Quanta Services Inc trades at $647.43 (market cap $98.82B). The key difference: Quanta Services Inc is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Quanta Services Inc pays a 0.07% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PWR | |
|---|---|---|
Market Cap | $39.89B | $98.82B |
Sector | Health | Industrials |
52-Week High | $491.22 | $785.24 |
52-Week Low | $278.09 | $372.50 |
Enterprise Value | $38.15B | $104.78B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Quanta Services (PWR) trades at $658.56, down 1.44% with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth has been robust, increasing from $17.1B in 2022 to $28.5B in 2025, though profit margins remain modest at 3.67%. Analyst sentiment remains overwhelmingly positive with 27 buy ratings and a consensus price target of $836.80, representing 27% upside potential.
PWR presents a compelling growth story driven by infrastructure spending and AI-related opportunities, with management projecting technology revenues to rise over 110% by 2030. However, the stock trades at premium valuations (P/E 90.34) and faces execution risks from aggressive capital expenditure plans. The bearish technical setup suggests near-term pressure, but strong institutional support and massive infrastructure backlog provide long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
